Has Janie Yang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $156,146 in general payments to Janie Yang, MD across 752 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Janie Yang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Janie Yang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Janie Yang, MD

Gastroenterology · New York, NYNPI 1346668423

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $116,500 of the $156,146 with a category attached, or 74.6%. Lilly USA, LLC accounts for 87.8% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $94,265, more than ten times the $140 reported in 2020. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$156,146in general payments, 2019–2025

Across 752 payments — averaging $207.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$137K
E.r. Squibb & Sons, L.L.C.$5K
Bristol Myers Squibb$4K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
AbbVie$1K
Johnson & Johnson$1K
plus $5K from 19 others

What the payments were for

Consulting fees$3,6302%
Speaking & faculty fees$116,50075%
Travel & lodging$18,48712%
Food & beverage$17,42911%
Education$1000%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	201	$137,075
E.r. Squibb & Sons, L.L.C.	8	$5,083
Bristol Myers Squibb	93	$3,687
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	169	$2,615
AbbVie	45	$1,298
Johnson & Johnson	36	$1,166
QOL Medical, LLC	41	$1,125
Pfizer	44	$739
Merck	21	$545
Takeda Pharmaceuticals U.S.A., Inc.	22	$502
Janssen Scientific Affairs, LLC	3	$446
Braintree Laboratories, Inc.	15	$353
Ironwood Pharmaceuticals, Inc	14	$261
Madrigal Pharmaceuticals	5	$233
Sanofi	5	$211
Regeneron Healthcare Solutions, Inc.	9	$192
Ardelyx, Inc.	7	$170
Amgen	5	$156
Novo Nordisk	1	$123
Ferring Pharmaceuticals Inc.	2	$53
Redhill Biopharma Inc.	2	$25
Vibrant Gastro, Inc.	1	$25
Aimmune Therapeutics, Inc.	1	$25
Endo Pharmaceuticals Inc.	1	$21
Phathom Pharmaceuticals, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OMVOH$111,453
Tremfya$446
STELARA$348
ZEPOSIA$275
Mavyret$273
Rinvoq$150
Sotyktu$129
Sucraid$125
REZDIFFRA$123
Wegovy$123
DUPIXENT$115
LINZESS$106

How this compares

$156,146 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$26,189

Medicare patients

Services billed

153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	17	$939
Pantoprazole Sodium	16	$118

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

David Carr LockeNew York$2M
Arthur KornbluthNew York$1.9M
Sonal KumarNew York$1M
David PoppersNew York$939K
Ellen ScherlNew York$857K
Bruce SandsNew York$810K
Jean Frederick ColombelNew York$786K
Seth GrossNew York$624K
Caterina Oneto ArayaNew York$610K
Dana LukinNew York$491K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →